A comparative study of efficacy of single dose of intravenous ferric carboxymaltose over oral iron therapy in severe iron deficiency Anemia

 

 

Abstract              Background: Iron deficiency anemia (IDA) is a very common hematological complication with a global prevalence of 2% among adult men and 9–20% among adult women both pregnant and non-pregnant, depending on race and ethnicity. Objectives: to compare the efficacy of intravenous ferric carboxymaltose over oral iron therapy in adult males and non-pregnant females with severe iron deficiency anemia. Methodology: observational comparative study, carried out in a tertiary care hospital in western Maharashtra for a period of 6 months with a sample size of 100 patients. 50 cases each of anaemic patients treated with iv. Ferric Carboxymaltose and oral iron therapy. The iv. Ferric Carboxymaltose was given in two doses of 15 mg/kg (750mg) seven days apart, and oral iron tablets with 200 mg of elemental iron daily. The data was entered in Microsoft excel and was analysed using EpiInfo software. Results: There were 38 males and 62 females in the study, in which 20 males received oral therapy while 18 received IV. Ferric Carboxymaltose, amongst females, 30 received oral therapy while rest 32 received IV. Ferric Carboxymaltose therapy. The mean levels of Hb in males at the start of the treatment was 7.2 ± 0.8 g/dL, while in females it was 6.7 ± 1.3 g/dL. Interpretation: Salve M.P. at el which showed that target Hb levels were achieved significantly in even a single dose of IV. Ferric Carboxymaltose compared to oral iron. Conclusion: Intravenous Ferric Carboxymaltose is a very effective mode of treatment.

Keywords: Anemia, Iron deficiency, Ferric Carboxymaltose, oral iron.